Clinical Trial Update: Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone [Phase 2]

View source ↗

Summary

Phase IIb study evaluating different oral doses of BAY94-8862 in chronic heart failure with left ventricular systolic dysfunction, with or without type 2 diabet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• BAY94-8862

Snippet

Sponsor: Bayer | Conditions: Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2021-06-15